跳至主要内容
临床试验/NCT01341327
NCT01341327招募中不适用

A GLOBAL, MULTICENTER, PROSPECTIVE, REAL WORLD OBSERVATIONAL STUDY FOR LEFT MAIN DISEASE TREATMENT

Seung-Jung Park42 个研究点 分布在 5 个国家目标入组 10,000 人开始时间: 2007年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
10,000
试验地点
42
主要终点
Composite event rate of death, myocardial infarction, Target Vessel Revascularization or cerebrovascular event

研究概览

简要总结

The purpose of this study is to observe clinical courses for long-term in patients with unprotected LMCA disease and to evaluate comparative results of medical treatment, coronary stenting with drug-eluting stents, and CABG for the treatment of an unprotected LMCA stenosis in the "real world" daily practice.

详细描述

This study is a multicenter, large clinical registry to evaluate comparative outcomes of medical therapy, PCI with DES, or CABG for patients with unprotected LMCA stenosis in the Asia-Pacific, as recorded in the MAIN-IRIS Registry. Data will be prospectively collected on approximately 5000 subjects who diagnosed LM disease (>50% by visual estimation) at approximately 65 centers in Korea and Asia-Pacific region. Brief study design is as depicted in the following figure

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Significant unprotected left main stenosis (>50% by visual estimation)
  • The LMCA is considered unprotected if there are no patent coronary artery bypass grafts to the left anterior descending artery or the left circumflex artery.
  • No limitation of clinical or lesion characteristics
  • Age >18 years
  • The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.

排除标准

  • Protected left main stenosis

结局指标

主要结局

Composite event rate of death, myocardial infarction, Target Vessel Revascularization or cerebrovascular event

时间窗: 2-year

A composite endpoint is an endpoint that is a combination of multiple clinical endpoints. An event that is considered to have occurred if any one of several different events is observed.

次要结局

  • Death(10-year)
  • Myocardial infarction(10-year)
  • Target vessel revascularization(10-year)
  • Cardiac death(10-year)
  • Cerebrovascular event(10-year)
  • Target lesion revascularization(10-year)
  • Stent thrombosis(10-year)
  • Binary restenosis and late luminal loss in both in-stent and in-segment(9-month)
  • Rehospitalization(10-year)

研究者

发起方
Seung-Jung Park
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Seung-Jung Park

MD,PhD, Chairman,Heart Institute, Asan Medical Center,University of Ulsan,College of Medicine

CardioVascular Research Foundation, Korea

研究点 (42)

Loading locations...

相似试验